Cite
HARVARD Citation
Blaettler, T. et al. (n.d.). P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer's Disease. Alzheimer's & dementia. p. P609. [Online].